Vestmark Advisory Solutions Inc. Has $15.49 Million Stake in CRISPR Therapeutics AG $CRSP

Vestmark Advisory Solutions Inc. trimmed its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 50.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 238,962 shares of the company’s stock after selling 246,013 shares during the period. Vestmark Advisory Solutions Inc. owned 0.26% of CRISPR Therapeutics worth $15,487,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its position in shares of CRISPR Therapeutics by 5.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after purchasing an additional 180 shares during the period. Cerity Partners LLC grew its stake in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after buying an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp raised its holdings in CRISPR Therapeutics by 3.0% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after acquiring an additional 200 shares during the period. Ipswich Investment Management Co. Inc. lifted its position in CRISPR Therapeutics by 0.9% during the 3rd quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company’s stock worth $1,633,000 after acquiring an additional 230 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in CRISPR Therapeutics by 1.1% during the second quarter. Teacher Retirement System of Texas now owns 22,066 shares of the company’s stock valued at $1,073,000 after acquiring an additional 243 shares during the period. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,112 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total transaction of $111,048.96. Following the completion of the transaction, the general counsel owned 85,115 shares in the company, valued at $4,475,346.70. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 60,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the transaction, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at approximately $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 99,079 shares of company stock valued at $5,643,674. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Trading Down 2.2%

Shares of NASDAQ CRSP opened at $53.46 on Friday. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $78.48. The business has a fifty day simple moving average of $53.84 and a 200 day simple moving average of $57.24. The firm has a market capitalization of $5.13 billion, a price-to-earnings ratio of -8.20 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company’s quarterly revenue was down 97.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.01) EPS. On average, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Pipeline and earnings reaction — MarketBeat notes investors cheered Q4 results for pipeline progress and CASGEVY adoption (cash runway ~ $1.9B, CTX611 upside). That optimism helped the stock rebound after earnings even though reported revenue was small due to revenue-sharing with Vertex. CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
• Positive Sentiment: Bull case on long-term upside — Seeking Alpha highlights a “Buy” thesis driven by CASGEVY launch economics and CTX611 potential (modeled high peak sales), arguing significant upside exists despite high risk. Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
• Neutral Sentiment: Short-interest data ambiguous — reported short interest entries show zero shares/NaN changes and a 0.0 days ratio, which appears to be a reporting artifact rather than meaningful positioning information. No clear short-squeeze or build-up signal.
• Neutral Sentiment: Reassessment pieces — coverage (Yahoo) asks whether the recent rebound warrants a rethink, reflecting mixed analyst views and technical levels to watch; useful for investors weighing timing. Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Share Price Rebound?
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni and General Counsel James Kasinger sold shares on Feb 19 (CEO ~6,967 shares; GC ~2,112 shares), modestly reducing their positions. Insider sales can signal near-term caution to some investors. CEO Filing GC Filing
• Negative Sentiment: Near-term fundamentals and skepticism — Q4 showed a big EPS miss and revenue limited by a revenue-share with Vertex; some analysts (e.g., Morgan Stanley cited in coverage) remain cautious with low price targets. Pessimistic takes (Fool) question the long-term payoff versus risk. Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of recent analyst reports. Morgan Stanley reiterated an “underweight” rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Citizens Jmp cut their price target on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Royal Bank Of Canada increased their price objective on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 11th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Finally, Chardan Capital increased their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a report on Saturday, February 14th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.